- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05895045
Yoga for Treatment of Overactive Bladder in Pediatric Patients
Study Overview
Status
Intervention / Treatment
Detailed Description
Detrusor overactivity, otherwise known as overactive bladder (OAB) is the most common disease of voiding dysfunction in children and is characterized by urgency with or without incontinence. Current understanding of OAB suggests that it is a component of central sensitization whereby the central nervous system is in a persistent state of high reactivity. In this state, patients have lower thresholds for pain and for normal physiologic signals such as the sensation of bladder fullness. Yoga has been shown to favor parasympathetic output and appears to be effective in reversing central sensitization for patients with chronic pain. Further, both central sensitization and OAB have been associated with inflammation and so observation of urinary markers of inflammation allow an objective measurement, along with subjective symptom reporting, to measure treatment effects. Children with OAB are likely to become adults with similar urinary complaints and are also more likely to have anxiety, depression and other problems throughout development and maturation. Treatment for OAB in children is comprised of first conservative management with behavioral therapies including biofeedback, subsequent addition of pharmacologic treatment options and finally more invasive therapies including intradetrusor botulinum toxin injections and neuromodulation.
Yoga has been shown to have some positive health benefits in pediatric patients with pulmonary dysfunction, epilepsy, anxiety/depression and even in pediatric oncology patients with regards to quality of life during treatment. Additionally, yoga has been assessed as an adjunctive therapy for the treatment of urinary incontinence and overactive bladder in predominantly adult female populations. That said, to date there have been no studies assessing the impact of yoga on detrusor overactivity in pediatric patient populations (< 19 years old). This is a pilot study in which the investigators hypothesize that yoga will lead to improved quality of life, reduced urinary symptoms and reduced expression of inflammatory urinary biomarkers.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Rafael Tua-Caraccia, MD
- Phone Number: 7865546150
- Email: rdt25@duke.edu
Study Contact Backup
- Name: Jonathan Routh, MD, MPH
- Phone Number: (919) 684-6994
- Email: jonathan.routh@duke.edu
Study Locations
-
-
North Carolina
-
Durham, North Carolina, United States, 27701
- Recruiting
- Duke University Hospital
-
Contact:
- Jonathan Routh, MD, MPH
- Phone Number: 919-684-6994
- Email: jonathan.routh@duke.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 8-18 years of age
- History of non-neurogenic overactive bladder or detrusor overactivity and/or urinary incontinence (ICD 10 codes respectively - N32.81, N39.498)
- Obtained legally effective informed consent and Health Insurance Portability and Accountability Act (HIPPA) authorization from the participant or the participant's parent/legal guardian
- Minor participant is willing and able to provide assent (as applicable)
- Vancouver Dysfunctional Elimination Syndrome[15] score of ≥11 and a positive modified bother score within 30 days of consent
Exclusion Criteria:
- Known or apparent untreated anatomical abnormality of lower urinary tract (i.e. untreated ureterocele)
- Known neurogenic bladder (e.g., spina bifida, history of spinal cord injury, tethered cord)
- Nerve damage that may impact pelvic floor function
- History of chemodenervation of the bladder (e.g., via intravesical instillation or intradetrusor injection of botulinum toxin)
- Active, untreated UTI at the time of enrollment (UTI undergoing active treatment is allowable)
- Current or previous pregnancy at screening or planned pregnancy during the duration of the study, for females of childbearing potential
- Any condition that, in the judgment of the investigator or treating clinician, precludes participation because it could affect participant safety
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1.1: 8-12 yoga first
|
Restorative Vinyasa Yoga
|
Experimental: 1.2: 13-18 yoga first
|
Restorative Vinyasa Yoga
|
Experimental: 2.1: 8-12 yoga second
|
Restorative Vinyasa Yoga
|
Experimental: 2.2: 13-18 yoga second
|
Restorative Vinyasa Yoga
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in overactive bladder symptoms
Time Frame: 0, 6 and 12 weeks
|
Measured via Vancouver symptom score for Dysfunctional Elimination Syndrome with modified bother score (both parts of same survey assessment to be filled out).
VDES score ranging from 5-65 with higher number representing worse symptoms; modified bother score ranges from 1-4 with 1= never bothered and 4= always bothered
|
0, 6 and 12 weeks
|
Change in expression of nerve growth factor
Time Frame: 0, 6 and 12 weeks
|
nerve growth factor urinary biomarker via urine specimen collection
|
0, 6 and 12 weeks
|
Change in expression of interleukin - 1B
Time Frame: 0, 6 and 12 weeks
|
Interleukin-1B urinary biomarker via urine specimen collection
|
0, 6 and 12 weeks
|
Change in expression of tumor necrosis factor-alpha
Time Frame: 0, 6 and 12 weeks
|
tumor necrosis factor-alpha urinary biomarker via urine specimen collection
|
0, 6 and 12 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Pro00112833
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Overactive Bladder
-
Ankara Yildirim Beyazıt UniversityCompletedOveractive Bladder | Overactive Detrusor | Overactive Bladder SyndromeTurkey
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedOveractive Bladder (OAB)United States, Canada, Germany, Korea, Republic of, Spain, Turkey, Taiwan, Italy, Slovakia, Denmark, South Africa, United Kingdom, Mexico, Sweden, Norway
-
Medstar Health Research InstituteColumbia University; University of Michigan; University of New Mexico; Methodist...Terminated
-
Astellas Pharma Global Development, Inc.CompletedOveractive Bladder (OAB)United States, Canada
-
Merck Sharp & Dohme LLCTerminatedOveractive Bladder | Overactive Urinary Bladder
-
Loyola UniversityAstellas Pharma IncCompletedOveractive Bladder SyndromeUnited States
-
Beijing Pins Medical Co., LtdUnknown
-
Maastricht University Medical CenterUnknownLower Urinary Tract Symptoms | Overactive Bladder SyndromeNetherlands
-
Pamukkale UniversityCompletedElectrical Stimulation | Idiopathic Overactive Bladder | Bladder TrainingTurkey
Clinical Trials on Yoga
-
Universität Duisburg-EssenCompleted
-
University of Texas at AustinCompleted
-
Adiyaman University Research HospitalCompletedDepression | Stress | Anxiety | Psychological ResilienceTurkey
-
NMP Medical Research InstituteYog-Kulam; Department of Zoology, University of Rajasthan, IndiaCompleted
-
NMP Medical Research InstituteWarwick Research Services; Yog-KulamCompleted
-
Northwestern UniversityCompleted
-
University of MinnesotaCompleted
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedDepression | Pain | Breast Cancer | FatigueUnited States
-
Emory UniversityNational Cancer Institute (NCI); National Institutes of Health (NIH)Active, not recruitingProstate CarcinomaUnited States
-
Manhattan Physical Medicine and Rehabilitation,...New York UniversityCompleted